-Kah-Whye Peng Researcher Activity Profile

Research Author Detailed Information 

Kah-Whye Peng Publication Rate By Year

Kah-Whye Peng has published 3 paper(s) in 2006, 10 paper(s) in 2007, for a total of 13 research publications in total.

Kah-Whye Kw Peng Author Information

LAST NAME: peng

FIRST NAME: Kah-Whye

INITIALS: kw

AFFILIATION:

Papers

Kah-Whye Peng's Publication Record

1. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Year Published: 2006
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
2. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Year Published: 2006
Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA.
3. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Year Published: 2006
Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA.
4. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Year Published: 2007
1Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
5. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Year Published: 2007
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
6. Viruses as anticancer drugs. Year Published: 2007
Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. sjr@mayo.edu
7. Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells. Year Published: 2007
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA. thatcher@uic.edu
8. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. Year Published: 2007
Department of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 S Wood St, Chicago, IL, 60612, USA, Fax: (+1) 312-996-7107.
9. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Year Published: 2007
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
10. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Year Published: 2007
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
11. Affinity thresholds for membrane fusion triggering by viral glycoproteins. Year Published: 2007
Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
12. Affinity thresholds for membrane fusion triggering by viral glycoproteins. Year Published: 2007
Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
13. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Year Published: 2007
1Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.